Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments

Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance

LuAnn Sabounjian Named Vice President, Clinical Operations

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. announced today the appointment of Mark Roessel to Vice President of Regulatory Affairs and Quality Assurance and LuAnn Sabounjian to Vice President, Clinical Operations. Both Mr. Roessel and Ms. Sabounjian are appointed to key roles in expanding Concert’s development pipeline and will report to Dr. James Shipley, Concert’s Chief Medical Officer.

“As we continue to expand our clinical pipeline, we expect these accomplished leaders will make significant contributions to key aspects of the regulatory and clinical activities necessary to effectively advance our programs from research into and through clinical development,” said James E. Shipley, M.D., Chief Medical Officer of Concert Pharmaceuticals. “It’s a pleasure to welcome both Mark and LuAnn to Concert and we look forward to the impact they’ll make to further advance our clinical pipeline of novel deuterated drug compounds.”

Over the past 15 years, Mr. Roessel has held leadership regulatory positions within the biotechnology industry with a demonstrated track record of successful regulatory submissions across all stages of drug development. Before Concert, he served as Vice President of Regulatory Affairs at Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals. Prior to Indevus, he was Vice President Regulatory Affairs and Quality Assurance at AMAG Pharmaceuticals. He has extensive experience in global drug development including CMC activities, planning and designing clinical and preclinical studies, preparing submissions and interfacing with regulatory authorities. Mr. Roessel is a board certified member of the Regulatory Affairs Professionals Society.

Ms. Sabounjian has a track record of over 20 years of diverse accomplishments in the pharmaceutical industry, including drug development, research and development operations, and medical and scientific support of marketed products. She has held key roles in the development of diverse compounds in neurology, endocrinology, HIV prevention, oncology and psychiatry, among other therapeutic areas. She joins Concert following a 20 year career at Indevus Pharmaceuticals where she held a variety of clinical roles of increasing responsibility, most recently as Vice President of Clinical Development. At Indevus, she organized and implemented clinical trials leading to the approval of four new chemical entities. Before joining the industry she was an Epilepsy Research Nurse and Clinician at Beth Israel Hospital in Boston. Ms. Sabounjian is a graduate of the Boston College School of Nursing and expects to complete her MBA and MSN degrees next year.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease, renal disease and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.



CONTACT:

Concert Pharmaceuticals
Justine E. Koenigsberg, 781-674-5284 (Investors)
or
The Yates Network
Kathryn Morris, 845-635-9828 (Media)

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.